
What the FDA's July 2026 Peptide Review Means for You
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee meets to decide whether seven peptides should be eligible for compounding. If you use BPC-157, TB-500, or any of the others on the list, this meeting affects whether you can legally obtain them. Here is what is actually being decided, what it is not, and what it means for you.